Skip to main content
OpenTrials
Completed

NCT Number: NCT01097434

Test Safety of Biodegradable and Permanent Limus-Eluting Stents Assessed by Optical Coherence Tomography

The objective of the study is to assess the superiority of the biodegradable polymer based limus-eluting stent (Nobori®) compared with the permanent polymer based everolimus-eluting stent (XIENCE V®) regarding absolute percentage of uncovered stent strut segments.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Deutsches Herzzentrum Muenchen

Munich, 80636, Germany

About this study

The mid-term efficacy of drug-eluting stents has been well-established, but there is an ongoing debate on the potential of an increased incidence of late stent thrombosis, particularly after discontinuation of thienopyridine therapy, as well as of delayed onset of restenosis or catch-up phenomenon with permanent polymer-based DES. The extent of strut coverage with reduction of exposed thrombogenic material has been shown to be associated with the inflammatory reaction grade and with the incidence of stent thrombosis. The optical coherence tomography (OCT) is an intravascular imaging modality based on light. The principle is similar to intravascular ultrasound, but due to the much shorter wave length of light, it offers a much better resolution up to 10µm, enabling the exact determination of strut coverage, neointimal thickness, vessel size, presence of dissections, and even the presence of inflammation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥ 50% stenosis located in native coronary vessels
  • Written, informed consent by the patient or her/his legally-authorized representative for participation in the study
  • In women with childbearing potential a negative pregnancy test is mandatory

Exclusion criteria

  • Lesion length >16mm requiring a stent length >18mm
  • Target lesion located in the left main trunk
  • In-stent restenosis
  • Acute myocardial infarction
  • Malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than 12 months or that may result in protocol non-compliance
  • Known allergy to the study medications: rapamycin, everolimus, biolimus, stainless steel or cobalt chrome
  • Inability to take dual antiplatelet therapy for at least 6 months
  • Pregnancy (present, suspected or planned) or positive pregnancy test
  • Previous enrollment in this trial
  • Patient's inability to fully cooperate with the study protocol

Treatment and study plan

Biodegradable polymer limus-eluting stents

Device

due randomization biodegradable polymer limus-eluting stents will be implanted

Other names: Nobori®

Permanent polymer limus-eluting stent

Device

due randomization permanent polymer limus-eluting stent will be implanted

Other names: Xience-V®

Primary outcomes

  1. Percentage of uncovered stent strut segments assessed by OCT

    Time frame: 6-8 months

Secondary outcomes

  1. Percentage of malposed stent strut segments assessed by OCT

    Time frame: 6-8 months

Sponsors and collaborators

Lead sponsor

Deutsches Herzzentrum Muenchen

Other

Registry information

Official study title

Randomized Comparison of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coating Regarding Stent Coverage Assessed by Optical Coherence Tomography

Acronym: TEST-6-OCT

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Apr 1, 2010
Registry last updated
Jan 13, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.